Third Rock raises $516m for early-stage venture deals
This article was originally published in Scrip
Executive Summary
Third Rock Ventures has raised $516 million for its third life science venture capital fund with a primary focus on therapeutics startups, bringing the Boston-based firm's total capital raised since 2007 to $1.3 billion - all to finance early-stage companies.
You may also be interested in...
VC Roundup: October Brings Several New Venture Funds, Including Third Rock’s Fourth
Third Rock closed a $616m venture capital fund, exceeding the firm’s goal of $600m to fund newly formed biopharma companies, following Sofinnova and others with new VC and debt funds for early- to mid-stage life science companies. Also, five drug developers raised $256m in new VC cash.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.